Paternostro, Rafael http://orcid.org/0000-0002-1813-5769
Staufer, Katharina
Traussnigg, Stefan
Stättermayer, Albert-Friedrich
Halilbasic, Emina
Keritam, Omar
Meyer, Elias L.
Stift, Judith
Wrba, Fritz
Sipos, Bence
Canbay, Ali
Schlattjan, Martin
Aigner, Elmar
Datz, Christian
Stickel, Felix
Schafmayer, Clemens
Hampe, Jochen
Buch, Stephan
Prager, Gerhard
Munda, Petra
Mandorfer, Mattias
Ferenci, Peter
Trauner, Michael
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 28 January 2021
Accepted: 24 April 2021
First Online: 2 June 2021
Declarations
:
: RP, KS, ST, AFS, EH, OK, JS, FW, BS, AC, MS, CD, CS, JH, SB, GP, PF, PM: none. FS: None in relation to the contents of this study. EM: reports funding for unrelated research from Novartis. EA: speaker fees, travel support or advisory fees from Intercept, Gilead, Takeda, Shire, Alexion; MM received speaker fees from AbbVie, Bristol-Myers Squibb, Gilead, and W. L. Gore and Associates; travel support from AbbVie, Bristol-Myers Squibb, and Gilead. PF: Adboard: Univar, Alexion and Vivet Therapeutics, Gliead, Abbvie, MSD. MT received speaker fees from Bristol-Myers Squibb (BMS), Falk Foundation, Gilead, Intercept and Merck Sharp and Dohme (MSD); advisory board fees from Albireo, Boehringer Ingelheim, BiomX, Falk Pharma GmbH, GENFIT, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, Regulus and Shire; travel grants from AbbVie, Falk, Gilead, and Intercept; and research grants from Albireo, CymaBay, Falk, Gilead, Intercept, MSD, and Takeda. He is also coinventor of patents on the medical use of norUDCA filed by the Medical University of Graz. All the other authors declare no conflicts of interest.
: The study was approved by the ethics committee of the Medical University of Vienna (EK 747/2011) and the local ethics committees of the participating centers and performed in accordance with the current version of the Helsinki Declaration. All patients signed an informed consent form prior to study inclusion.